

Date: 8 November 2019

Re: Freedom of Information Request
Ref: 247 - 2019

Thank you for your email dated the 5th September 2019, requesting information regarding cancer treatments with the organisation.

The information that you require is as follows:

Please note, in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

1 - How many melanoma patients undergoing treatment are BRAF+?

- **When looking at Melanoma patients receiving SACT with PALLIATIVE intent (as requested via clarification) between 1st June 2019 and 31st August 2019 the figures are as follows:**
 - **27 were BRAF positive**
 - **44 were BRAF negative**
 - **BRAF not known – Exempt under S.40**
 - **56 were BRAF not recorded**

- When looking at Melanoma patients receiving SACT with ANY intent (as requested via clarification) between 1st June 2019 and 31st August 2019 the figures are as follows:
 - 44 were BRAF positive
 - 59 were BRAF negative
 - BRAF not known – Exempt under S.40
 - 67 were BRAF not recorded

1a -In the past 3 months, how many melanoma patients were treated with the following with PALLIATIVE intent with:

Bevacizumab = 0 patients

Cobimetinib = 0 patients

Dabrafenib = Exempt under S.40

Dabrafenib AND trametinib = 20 patients

Dacarbazine = 0 patients

Encorafenib AND binimetinib = 0 patients

Ipilimumab = Exempt under S.40

Ipilimumab AND Nivolumab = 10 patients

Nivolumab = 32 patients

Pembrolizumab = 62 patients

Trametinib = 0 patients

Vemurafenib = 0 patients

Vemurafenib AND Cobimetinib = 0 patients

Other active systemic anti-cancer therapy Palliative care = 7 patients (all on clinical trials)

1b - In the past 3 months how many patients were seen who had stage III resectable melanoma

As we are a tertiary specialist cancer treatment centre, this question is not applicable to our Trust.

1c - Of all stage III patients seen, how many received a complete resection?

As we are a tertiary specialist cancer treatment centre, this question is not applicable to our Trust.

1d - Of all stage III patients seen, how many were stage III a?

As we are a tertiary specialist cancer treatment centre, this question is not applicable to our Trust.

2 - In the past 3 months, how many Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with PALLIATIVE intent with:

Afatinib = 0 patients

Atezolizumab monotherapy = 8 patients

Bevacizumab = 0 patients

Docetaxel monotherapy = Exempt under S.40

Durvalumab = 0 patients

Erlotinib = 0 patients

Gemcitabine = 0 patients as monotherapy

Necitumumab = 0 patients

Nivolumab = 9 patients

Paclitaxel = 0 patients

Pembrolizumab monotherapy = 43 patients

Pembrolizumab chemo in combination = 0 patients

Pemetrexed = 0 patients as monotherapy

Ramucirumab = 0 patients

Vinorelbine and cisplatin / carboplatin = 10 patients

Other active systemic anti-cancer therapy [please state] Palliative care only = Crizotinib - Exempt under S.40

3 - In the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with PALLIATIVE intent with:

Afatinib = 42 patients

Alectinib = 12 patients

Atezolizumab mono = 16 patients

Atezolizumab + bevacizumab + carboplatin + paclitaxel = Exempt under S.40

Bevacizumab = 0 patients

Brigatinib = Exempt under S.40

Ceritinib = Exempt under S.40

Crizotinib = Exempt under S.40

Dacomitinib = 0 patients

Docetaxel monotherapy = Exempt under S.40

Erlotinib = 11 patients

Gefitinib = 9 patients

Nintedanib with docetaxel = Exempt under S.40

Nivolumab = Exempt under S.40

Osimertinib = 15 patients

Paclitaxel = 0 patients

Pembrolizumab monotherapy = 93 patients

Pembrolizumab chemo in combination = 51 patients

Pemetrexed with carboplatin = 15 patients

Pemetrexed with cisplatin = Exempt under S.40

Ramucirumab = 0 patients

Other active systemic anti-cancer therapy [please state] Palliative care only:

Atezolizumab Bevacizumab = Exempt under S.40

Capecitabine = Exempt under S.40

Capecitabine + Oxaliplatin = Exempt under S.40

Carboplatin + Vinorelbine = 17 patients

Cisplatin + Etoposide = Exempt under S.40

Cisplatin + Gemcitabine = Exempt under S.40

Cisplatin + Vinorelbine = Exempt under S.40

Durvalumab = Exempt under S.40

Everolimus = Exempt under S.40

GemCarbo = 9 patients

Lorlatinib = Exempt under S.40

Nintedanib = Exempt under S.40

Octreotide = Exempt under S.40

Pemetrexed = 14 patients

Sirolimus = Exempt under S.40

4 - In the past 3 months, how many Urothelial cancer patients were treated with PALLIATIVE intent with;

Atezolizumab = 13 patients

Carboplatinum in combination with another agent = 14 patients

Carboplatinum single agent = 0 patients

Cisplatinum in combination with another agent = 8 patients

Cisplatinum single agent = 0 patients

Nivolumab = 21 patients as monotherapy

Pembrolizumab = 10 patients

Any other chemo regimen without cisplatinum or carboplatinum = 0 patients

Other active systemic anti-cancer therapy [please state] Palliative care only:

Axitinib = Exempt under S.40

Cabozantinib = 25 patients

Enfortumab Vedotin = Exempt under S.40

Everolimus = Exempt under S.40

Paclitaxel = Exempt under S.40

Pazopanib = 11 patients

Ramucirumab = Exempt under S.40

Rogaratinib = Exempt under S.40

Sunitinib = 7 patients

Tivozanib = 19 patients

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>